Phillip Securities Group
Please note that the Day Light Saving of Europe and US will be effective on April 1st and March 11th respectively. The trading hours for those relevant contracts will be 1 hour earlier. Any questions, please contact us at 22776677.For details, please visit our foreign futures website or contact us at 22776677.Moreover,the spread of USD/JPY is low as one pip.Please click here for details
 
  Phillip Investor Notes

05-09-2024(Thu) 04-09-2024(Wed) 03-09-2024(Tue) 02-09-2024(Mon) 30-08-2024(Fri)
Page : 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments ¤¤¤åª©
10 Dec, 2024 (Tuesday)



AKESO(9926)
Analysis¡G
US lawmakers are considering changes to the Biosafety Act, with the compromise version including increased administrative review of relevant companies instead of automatically banning biopharmaceutical companies from cooperating with Chinese companies. Since the fourth quarter of 2021, the biopharmaceutical sector has been adjusting its pessimistic expectations due to geopolitical games, fluctuations in investment and financing, recurring epidemics, and policy disturbances. The average PE ratio of core targets in 2024 is significantly discounted compared to the average PE ratio (TTM) in the past five years, and the current valuation level is near historical lows. Due to the continued rapid increase in downstream single-product volume, the demand for chemical large molecule CDMOs such as peptides and oligonucleotide CDMOs is expected to increase rapidly, and investment opportunities in related industry chains are still promising. With global investment and financing gradually recovering and front-end projects continuing to extend to the back-end, small molecule CDMOs are expected to gradually recover. Akeso is a biopharmaceutical company dedicated to researching, developing, producing, and commercializing innovative affordable antibodies for global patients. Since its establishment, the company has built an end-to-end comprehensive drug development platform covering integrated drug discovery and development functions, including target validation, antibody drug discovery and development, CMC production process development, and GMP-compliant production.
Strategy¡G
Buy-in Price: $66.00, Target Price: $72.60, Cut Loss Price: $55.00



JNBY Design Limited (3306.HK) - All three brands portfolio delivered revenue growth, with effective cost management

JNBY Design Limited (¡§JNBY¡¨), a leading designer-brand fashion group in China, demonstrated robust performance in the fiscal year ended June 30, 2024 (FY2024). Leveraging its diversified brand portfolio, solid business model, and operational excellence, JNBY has maintained a strong foothold in the competitive Chinese fashion market.

Effective cost management

In FY2024, JNBY reported total revenue of RMB 5.238 billion, a year-on-year increase of 17.3%. This growth was primarily driven by a 10.7% rise in comparable sales across physical stores, an 18.4% expansion in online sales, and a moderate increase in store footprint. Gross margin improved to 66.3% (FY2023: 65.3%), reflecting the Company's strong brand equity and effective cost management.

Net profit surged by 36.5% year-on-year to RMB 848.1 million, with the net profit margin increasing from 13.9% in FY2023 to 16.2% in FY2024. This demonstrates significant profitability improvement. Notably, net cash inflow from operating activities increased by 70.7% to RMB 1.603 billion, showcasing a robust cash position and strong operational efficiency. With a final dividend of HKD 0.86 per ordinary share, bringing the total dividend payout for FY2024 to 97% of net profit. This reflects the Company's solid cash flow and commitment to shareholder returns.

All three brands portfolio delivered revenue growth

JNBY's diversified brand portfolio spans mature brands (e.g., JNBY), growth brands (e.g., CROQUIS, jnby by JNBY, LESS), and emerging brands (e.g., POMME DE TERRE, onmygame, JNBYHOME). In FY2024, all three segments delivered revenue growth. Core brand JNBY posted revenue of RMB 2.944 billion, up 17.1% year-on-year, accounting for 56.2% of total revenue. Growth brands generated RMB 2.184 billion (+17.0% YoY), while emerging brands contributed RMB 109.8 million (+28.7% YoY). The diversified brand strategy enables JNBY to penetrate various consumer segments and mitigate risks while enhancing market share.

The Company's dual-channel strategy, encompassing an extensive offline retail network and strong online presence, has driven stable growth. Offline channels grew by 17.1% in revenue, while online channels achieved an 18.4% increase. JNBY's active membership accounts exceeded 550,000 in FY2024, with high-value members (annual spending above RMB 5,000) reaching over 310,000. These members contributed more than 60% of total offline retail sales, underscoring the Company's success in brand building and membership operations.

As of June 30, 2024, JNBY operated 2,024 independent retail stores worldwide, a net increase of 34 stores compared to FY2023. Its offline retail network covers all provinces in mainland China and nine other countries and regions globally. The launch of ¡§JIANGNANBUYI+¡¨ multi-brand collection stores and the upgrade of store visuals have enhanced the shopping experience, boosting comparable store sales and reinforcing the Company's brand presence.

With the steady recovery of China's economy and improving domestic consumption, JNBY is well-positioned to benefit from favorable market trends. The growing demand for designer brands, particularly among younger consumers seeking personalized and sustainable products, offers significant opportunities for the Company's multi-brand portfolio.

Meanwhile, the rapid growth of digital consumption and deeper integration of online and offline channels will create new growth drivers for JNBY. The Company's investments in smart supply chains, omnichannel marketing, and new retail formats position it to adapt quickly to market changes and solidify its leadership in the designer-brand segment.

Company valuation

Considering JNBY's strong financial performance, brand advantages, and industry prospects, we remain cautiously optimistic about its future. With a net profit margin of 16.2% and robust cash flow in FY2024, the Company demonstrates a solid foundation for sustained earnings growth, we expect FY2025E & FY2026E estimated basic EPS to be RMB$1.79 & RMB$1.85 respectively, with TP is HKD17.73, implies a FY2025E P/E of 9.0x (in line with its 5 years average +1 standard deviation) and FY2025E dividend yield of ~8.9%. Our investment rating is ¡§BUY¡¨.

Risk factors

1) Consumer Demand Volatility; 2) Intensified Brand Competition; and 3) Raw Material Cost Fluctuations.

Financial

Click Here for PDF format...




Recommendation on 10-12-2024
RecommendationBuy
Price on Recommendation Date$ 14.760
Suggested purchase priceN/A
Target Price$ 17.730
Writer Info
Eric Li
(Research Analyst)
Tel: (+852 2277 6516)
Email:
erichyli@phillip.com.hk

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the ¡§Group¡¨) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products¡¦ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

ª©Åv©Ò¦³¡A ½¦L¥²¨s¡C

Copyright(C) 2024 Phillip Securities (HK) Ltd. All Rights Reserved.


Copyright © 2011 Phillip Securities Group. All Rights Reserved [ Risk Disclosures Statement ] [ Terms and Conditions ] [ Personal Data Policy ]